Anesthetic Effect Duration Assessment
The purpose of this study is to evaluate the duration of anesthetic effect produced , Lidocaine7% + Tetracaine 7% cream when applied with 2 different application times on the face and thigh.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Anesthetic Effect Duration Produced by Lidocaine 7% + Tetracaine 7% Cream on 2 Different Body Areas|
- Duration of anesthesia [ Time Frame: From product removal up to T8 hours after product removal ] [ Designated as safety issue: No ]Duration of anesthesia will be the difference between the onset and end of anesthesia.
- Adverse Events [ Time Frame: At Baseline, Day 2 and Day 4 (at each study visit) ] [ Designated as safety issue: Yes ]Incidence of adverse events will be reported
|Study Start Date:||May 2012|
|Study Completion Date:||May 2012|
|Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
|Experimental: lidocaine 7% and tetracaine 7%||
Drug: Lidocaine 7% + Tetracaine 7% cream
Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
Subjects will have 4 target zones defined; 2 on the face and 2 on the anterior thighs. Upon inclusion into the study, subjects will have the study drug applied with a different application time to one side of the face and anterior thigh according to the randomization. After the completion of the application process, study drug on both sides of the face and on both anterior thighs will be removed by peeling.
After drug removal, the duration of anesthetic effect of the study drug will be tested using a pinprick test. Five (5) pinpricks using a 21-gauge needle will be performed at the 4 target zones (each side of the face and both anterior thighs). The pinprick test will be repeated up to 8 hours after drug removal. There will be a total of 20 post drug removal pinprick test completed.
|United States, New Jersey|
|Galderma Investigational center|
|Rochelle Park, New Jersey, United States|
|Principal Investigator:||Regina YAVEL, MD- Dermatologist||Galderma investigational center|